ArticleCureus2025
Medicaid Expansion and Survival Outcomes Among Men With Prostate Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Medicaid Expansion and Overall Mortality Among Individuals With Renal Cell Carcinoma.The Journal of surgical research · 2026Article
- Medicaid Expansion and Overall Mortality Among Individuals With Lung Cancer.The Journal of surgical research · 2026Article
- Medicaid expansion and overall mortality among women with cervical cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionProstate cancer stands as one of the most diagnosed malignancies among men worldwide. With the recent expansion of Medicaid under the Affordable Care Act (ACA), millions more Americans now have health insurance coverage, potentially influencing healthcare access and subsequent outcomes for various illnesses, including prostate cancer. Yet, the direct correlation between Medicaid expansion and cancer-specific survival among individuals with prostate cancer remains an area warranting comprehensive exploration.
objectiveThis study aims to determine the impact of the implementation of Medicaid expansion on survival outcomes among men with prostate cancer.
methodsWe utilized data from the Surveillance, Epidemiology, and End Results (SEER) registry to determine the causal impact of the implementation of the ACA on outcomes among men with prostate cancer. The study covered the years 2003-2021, divided into pre-ACA (2003-2009) and post-ACA (2015-2021) periods, with a one-year washout (2014-2015) since Medicaid expansion was implemented in 2014 in Kentucky. Using a difference-in-differences (DID) approach, we compared survival among men with prostate cancers from Kentucky to Georgia. We adjusted for patient demographics, income, metropolitan status, disease stage, and treatment modalities.
resultsWe analyzed a cohort of 68,222 men with prostate cancer during the study period. Of these, 37,810 (55.4%) were diagnosed in the pre-ACA period, with 70.8% from Georgia and 29.2% from Kentucky. The remaining 30,412 (44.6%) were diagnosed in the post-ACA period, with 72.3% from Georgia and 27.7% from Kentucky. Medicaid expansion in Kentucky was associated with a 16.8% reduction in the hazard of overall death, indicating improved overall survival among eligible individuals. This trend was consistent across different racial and ethnic groups. Specifically, non-Hispanic White men experienced a 16.2% reduction (DID=-16.2%; 95% CI: -31.5% to -0.8%), non-Hispanic Black men had a 17.9% reduction (DID=-17.9%; 95% CI: -34.8% to -0.9%), and Hispanic men saw a 15.9% reduction (DID=-15.9%; 95% CI: -31.3% to -0.5%) in hazard of death among low-income individuals.
conclusionMedicaid expansion was associated with a substantive improvement in overall survival among men with prostate cancer in Kentucky compared to non-expansion Georgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.